Amarantus Bioscience Holdings, Inc. - FORM 8-K - EX-99.14 OTH CONSENT - EXHIBIT 99.2 - May 27, 2011

Attached files

file filename
8-K - MAINBODY - Amarantus Bioscience Holdings, Inc.mainbody.htm
EX-3.2 - EXHIBIT 3.2 - Amarantus Bioscience Holdings, Inc.ex3_2.htm
EX-2.1 - EXHIBIT 2.1 - Amarantus Bioscience Holdings, Inc.ex2_1.htm
EX-3.1 - EXHIBIT 3.1 - Amarantus Bioscience Holdings, Inc.ex3_1.htm
EX-10.2 - EXHIBIT 10.2 - Amarantus Bioscience Holdings, Inc.ex10_2.htm
EX-10.8 - EXHIBIT 10.8 - Amarantus Bioscience Holdings, Inc.ex10_8.htm
EX-10.3 - EXHIBIT 10.3 - Amarantus Bioscience Holdings, Inc.ex10_3.htm
EX-10.7 - EXHIBIT 10.7 - Amarantus Bioscience Holdings, Inc.ex10_7.htm
EX-99.1 CHARTER - EXHIBIT 99.1 - Amarantus Bioscience Holdings, Inc.ex99_1.htm
EX-10.4 - EXHIBIT 10.4 - Amarantus Bioscience Holdings, Inc.ex10_4.htm
EX-10.5 - EXHIBIT 10.5 - Amarantus Bioscience Holdings, Inc.ex10_5.htm
EX-10.1 - EXHIBIT 10.1 - Amarantus Bioscience Holdings, Inc.ex10_1.htm
EX-10.6 - EXHIBIT 10.6 - Amarantus Bioscience Holdings, Inc.ex10_6.htm
EX-10.15 - EXHIBIT 10.1 - Amarantus Bioscience Holdings, Inc.ex10_15.htm
EX-10.12 - EXHIBIT 10.1 - Amarantus Bioscience Holdings, Inc.ex10_12.htm
EX-10.9 - EXHIBIT 10.9 - Amarantus Bioscience Holdings, Inc.ex10_9.htm
EX-10.10 - EXHIBIT 10.1 - Amarantus Bioscience Holdings, Inc.ex10_10.htm
EX-10.13 - EXHIBIT 10.1 - Amarantus Bioscience Holdings, Inc.ex10_13.htm
EX-10.11 - EXHIBIT 10.1 - Amarantus Bioscience Holdings, Inc.ex10_11.htm
EX-10.14 - EXHIBIT 10.1 - Amarantus Bioscience Holdings, Inc.ex10_14.htm

UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION.

On May 25, 2011, Amarantus Therapeutics, Inc. completed its merger with Jumpkicks, Inc. The following unaudited pro forma combined balance sheets and income statements are based on historical financial statements of the companies.  The unaudited pro forma combined financial statements are provided for information purposes only. The pro forma financial statements are not necessarily indicative of what the financial position or results of operations actually would have been had the acquisition been completed at the dates indicated below.  In addition, the unaudited pro forma combined financial statements do not purport to project the future financial position or operating results of the combined company.  The unaudited pro forma combined financial information has been prepared in accordance with the rules and regulations of the Securities and Exchange Commission. For pro forma purposes:

•  
The unaudited Pro Forma Combined Balance Sheets as of December 31, 2010 and October 31, 2010 combines the historical balance sheets of the companies as of the years ended December 31, 2010 and October 31, 2010, giving effect to the merger as if it had occurred at the beginning of the most recent year ended.  
•  
The unaudited Pro Forma Combined Statements of Operations for the years ended December 31, 2010 and October 31, 2010 combines the historical income statements of the companies for the indicated period, giving effect to the merger as if it had happened at the beginning of the most recent year ended.
•  
The unaudited Pro Forma Combined Balance Sheets as of December 31, 2009 and October 31, 2009 combines the historical balance sheets of the companies as of the years ended December 31, 2009 and October 31, 2009, giving effect to the merger as if it had occurred at the beginning of the most recent year ended.  
•  
The unaudited Pro Forma Combined Statements of Operations for the years ended December 31, 2009 and October 31, 2009 combines the historical income statements of the companies for the indicated period, giving effect to the merger as if it had happened at the beginning of the most recent year ended.


These unaudited pro forma combined financial statements and accompanying notes should be read in conjunction with the separate audited financial statements of Amarantus Therapeutics, Inc. and Jumpkicks, Inc. as of and for the years ended December 31, 2010 and October 31, 2010.

 
 
 
 
AMARANTUS THERAPEUTICS, INC.

TABLE OF CONTENTS


Pro Forma Combined Balance Sheets as of December 31, 2010 and October 31, 2010
2
   
Pro Forma Combined Statements of Operations for the years ended December 31, 2010 and October 31, 2010
3
   
Pro Forma Combined Balance Sheets as of December 31, 2009 and October 31, 2009
4
   
Pro Forma Combined Statements of Operations for the years ended December 31, 2009 and October 31, 2009
5
   
Notes to the Pro Forma Adjustments
6
 
 
 
 

AMARANTUS THERAPEUTICS, INC.
PRO FORMA COMBINED BALANCE SHEETS (UNAUDITED)
DECEMBER 31, 2010 AND OCTOBER 31, 2010


ASSETS
  
Amarantus Therapeutics, Inc.
December 31, 2010
    
Jumpkicks, Inc.
October 31, 2010
    
Pro Forma Adjustments
    
Total
  
Current Assets
                        
Cash and cash equivalents
   $ 47,521     $ 892           $ 48,413  
Accounts receivable
     0       0             0  
Prepaid expenses
     30,217       0             30,217  
Total Current Assets
     77,738       892             78,630  
                               
Property and Equipment, Net
     25,105       2,309             27,414  
                               
TOTAL ASSETS
   $ 102,843     $ 3,201           $ 106,044  
                               
LIABILITIES AND STOCKHOLDERS’ DEFICIT
                              
Current Liabilities
                              
Accounts payable
   $ 1,015,221     $ 0           $ 1,015,221  
Accrued expenses
     11,833       65,557             77,390  
Related party payables
     287,462       12,500             299,962  
Current portion of derivative liability
     141,690       0             141,690  
Current portion of convertible promissory notes
     1,094       0             1,094  
Total Current Liabilities
     1,457,300       78,057             1,535,357  
                               
Long-Term Liabilities
                              
Warrant liability
     4,416       0             4,416  
Derivative liability, net of current portion
     145,857       0             145,857  
Convertible promissory notes, net of current portion
     29,915       0             29,915  
Total Long-Term Liabilities
     180,188       0             180,188  
                               
TOTAL LIABILITIES
     1,637,488       78,057             1,715,545  
                               
STOCKHOLDERS’ DEFICIT
                              
Preferred stock
     685,342       0       (685,342 )a     0  
                      (4,020 )a        
                      10,000  b        
Common stock
     4,020       10,860       1,669  a     2,529  
                      (62,320 )a        
                      647,957  a        
Paid in capital
     62,320       16,340       10,000  b     674,297  
Accumulated deficit
     (2,286,327 )     (102,056 )     102,056  a     (2,286,327 )
TOTAL STOCKHOLDERS’ DEFICIT
     (1,534,645 )     (74,856 )             (1,609,501 )
                                 
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT
   $ 102,843     $ 3,201             $ 106,044  

See accompanying notes to the Pro Forma adjustments.
 
 
 
 
 
AMARANTUS THERAPEUTICS, INC.
PRO FORMA COMBINED STATEMENTS OF OPERATIONS (UNAUDITED)
YEARS ENDED DECEMBER 31, 2010 AND OCTOBER 31, 2010
 
   
Amarantus Therapeutics, Inc.
Year ended
December 31,
2010
    
Jumpkicks, Inc.
Year ended
October 31,
2010
  
Pro Forma
Adjustments
  
Total
  
                     
NET REVENUES
   $ 192,408     $ 0       $ 192,408  
                           
COSTS OF GOODS SOLD
     0       0         0  
                           
GROSS PROFIT
     192,408       0         192,408  
                           
OPERATING EXPENSES
     1,414,923       58,563         1,473,486  
                           
OPERATING LOSS
     (1,222,515 )     (58,563 )       (1,281,078 )
                           
OTHER INCOME (EXPENSE)
     14,954       0         14,954  
                           
NET LOSS BEFORE PROVISION FOR INCOME TAXES
     (1,207,561 )     (58,563 )       (1,266,124 )
                           
PROVISION FOR INCOME TAXES
     0       0         0  
                           
NET LOSS
   $ (1,207,561 )   $ (58,563 )     $ (1,266,124 )
                           
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING
     4,020,000       10,860,000         2,528,695  
                           
NET LOSS PER SHARE
   $ (0.30 )   $ (0.01 )     $ (0.50 )

See accompanying notes to the Pro Forma adjustments.
 
 
 
 
 
AMARANTUS THERAPEUTICS, INC.
PRO FORMA COMBINED BALANCE SHEETS (UNAUDITED)
DECEMBER 31, 2009 AND OCTOBER 31, 2009


ASSETS
  
Amarantus Therapeutics, Inc.
December 31, 2009
    
Jumpkicks, Inc.
October 31, 2009
  
Pro Forma Adjustments
  
Total
  
Current Assets
                    
Cash and cash equivalents
   $ 1,232     $ 282       $ 1,514  
Accounts receivable
     0       150         150  
Prepaid expenses
     0       0            
Total Current Assets
     1,232       432         1,664  
                           
Property and Equipment, Net
     1,382       3,521         4,903  
                           
TOTAL ASSETS
   $ 2,614     $ 3,953       $ 6,567  
                           
LIABILITIES AND STOCKHOLDERS’ DEFICIT
                          
Current Liabilities
                          
Accounts payable
   $ 371,852     $ 0       $ 371,852  
Accrued expenses
     47,024       8,746         55,770  
Related party payables
     295,888       11,500         307,388  
Current portion of derivative liability
     0       0         0  
Current portion of convertible promissory notes
     327,548       0         327,548  
Total Current Liabilities
     1,042,312       20,246         1,062,558  
                           
Long-Term Liabilities
                          
Warrant liability
     35,013       0         35,013  
Derivative liability, net of current portion
     0       0         0  
Convertible promissory notes, net of current portion
     0       0         0  
Total Long-Term Liabilities
     35,013       0         35,013  
                           
TOTAL LIABILITIES
     1,077,325       20,246         1,097,571  
                           
STOCKHOLDERS’ DEFICIT
                          
Preferred stock
     0       0            
Common stock
     4,020       10,860  
(4,020)a
1,669a
(10,000)b
     2,529  
Paid in capital
     35       16,340  
(35)a
(41,107)a
10,000b
     (14,767 )
Accumulated deficit
     (1,078,766 )     (43,493 )
43,493a
     (1,078,766 )
TOTAL STOCKHOLDERS’ DEFICIT
     (1,074,711 )     (16,293 )       (1,091,004 )
                           
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT
   $ 2,614     $ 3,953       $ 6,567  

See accompanying notes to the Pro Forma adjustments.
 
 
 
 
 
AMARANTUS THERAPEUTICS, INC.
PRO FORMA COMBINED STATEMENTS OF OPERATIONS (UNAUDITED)
YEARS ENDED DECEMBER 31, 2009 AND OCTOBER 31, 2009
 
   
Amarantus Therapeutics, Inc.
Year ended December 31, 2009
    
Jumpkicks, Inc.
Year ended October 31, 2009
  
Pro Forma Adjustments
  
Total
  
                     
NET REVENUES
   $ 0     $ 1,015       $ 1,015  
                           
COSTS OF GOODS SOLD
     0       1,165         1,165  
                           
GROSS PROFIT
     0       (150 )       (150 )
                           
OPERATING EXPENSES
     288,186       16,700         304,886  
                           
OPERATING LOSS
     (288,186 )     (16,850 )       (305,036 )
                           
OTHER INCOME (EXPENSE)
     (18,004 )     0         (18,004 )
                           
NET LOSS BEFORE PROVISION FOR INCOME TAXES
     (306,190 )     (16,850 )       (323,040 )
                           
PROVISION FOR INCOME TAXES
     0       0         0  
                           
NET LOSS
   $ (306,190 )   $ (16,850 )     $ (323,040 )
                           
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING
     4,020,000       10,860,000         2,528,695  
                           
NET LOSS PER SHARE
   $ (0.08 )   $ (0.00 )     $ (0.13 )

See accompanying notes to the Pro Forma adjustments.
 
 
 
 
 
AMARANTUS THERAPEUTICS, INC.
NOTES TO THE PRO FORMA ADJUSTMENTS (UNAUDITED)

 
(a) Issuance of 1,668,695 shares of common stock in connection with reverse merger of Amarantus Therapeutics, Inc. and Jumpkicks, Inc.

(b) Cancellation of 10,000,000 shares of common stock in connection with merger of Amarantus Therapeutics, Inc. and Jumpkicks, Inc.




















































6

 
 
 

Amarantus Bioscience Holdings, Inc. Reports